Raymond James Financial Inc. Acquires New Holdings in MiMedx Group, Inc. (NASDAQ:MDXG)

Raymond James Financial Inc. bought a new position in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 92,207 shares of the company's stock, valued at approximately $887,000. Raymond James Financial Inc. owned 0.06% of MiMedx Group as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in MDXG. Barclays PLC lifted its stake in shares of MiMedx Group by 163.9% in the 3rd quarter. Barclays PLC now owns 262,449 shares of the company's stock worth $1,550,000 after acquiring an additional 163,005 shares during the period. Principal Financial Group Inc. increased its holdings in shares of MiMedx Group by 6.3% in the 3rd quarter. Principal Financial Group Inc. now owns 55,495 shares of the company's stock valued at $328,000 after purchasing an additional 3,292 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of MiMedx Group by 265.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company's stock valued at $1,757,000 after purchasing an additional 215,995 shares in the last quarter. Fiduciary Alliance LLC purchased a new position in shares of MiMedx Group in the 4th quarter valued at about $160,000. Finally, SG Americas Securities LLC increased its holdings in shares of MiMedx Group by 79.9% in the 4th quarter. SG Americas Securities LLC now owns 83,385 shares of the company's stock valued at $802,000 after purchasing an additional 37,031 shares in the last quarter. Institutional investors and hedge funds own 79.15% of the company's stock.

Insider Transactions at MiMedx Group

In related news, CEO Joseph H. Capper bought 200,000 shares of the firm's stock in a transaction that occurred on Friday, May 2nd. The stock was purchased at an average price of $6.34 per share, for a total transaction of $1,268,000.00. Following the transaction, the chief executive officer now directly owns 529,530 shares of the company's stock, valued at approximately $3,357,220.20. This represents a 60.69% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO William Frank Iv Hulse sold 81,446 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $7.80, for a total transaction of $635,278.80. Following the completion of the transaction, the chief accounting officer now owns 494,774 shares of the company's stock, valued at $3,859,237.20. This represents a 14.13% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 144,018 shares of company stock worth $1,130,312. Insiders own 1.30% of the company's stock.

Wall Street Analyst Weigh In

MDXG has been the subject of several recent research reports. Cantor Fitzgerald restated an "overweight" rating and set a $13.00 target price on shares of MiMedx Group in a report on Thursday, February 27th. StockNews.com downgraded shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a report on Friday.

MiMedx Group Stock Down 4.0%

Shares of NASDAQ MDXG traded down $0.30 during trading on Friday, reaching $7.12. 1,111,673 shares of the stock were exchanged, compared to its average volume of 695,443. The business's 50-day moving average price is $7.28 and its 200 day moving average price is $8.15. MiMedx Group, Inc. has a twelve month low of $5.47 and a twelve month high of $10.14. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $1.05 billion, a price-to-earnings ratio of 12.95 and a beta of 1.85.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported $0.06 EPS for the quarter, meeting analysts' consensus estimates of $0.06. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The firm had revenue of $88.21 million for the quarter, compared to the consensus estimate of $86.32 million. As a group, equities analysts forecast that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.